Literature DB >> 3888428

Anticancer drug pharmacodynamics.

G Powis.   

Abstract

A considerable amount of information is available on the pharmacokinetics of anticancer drugs, but much less is known of their pharmacodynamics, that is of the relationship between therapeutic or toxic response and drug concentration. Drug dosage regimens which are to achieve defined therapeutic objectives can only be designed when both the pharmacokinetic and the pharmacodynamic characteristics of a drug are known. There are a few reports in the literature of relationships in man between toxic response and pharmacokinetic parameters of anticancer drugs, and an even smaller number of reports of relationships between therapeutic response and pharmacokinetic parameters. It is suggested that the lack of pharmacodynamic information is currently limiting the application of pharmacokinetic information to cancer therapy. Ways of improving knowledge of the pharmacodynamics of anticancer drugs are suggested.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888428     DOI: 10.1007/bf00258112

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  54 in total

1.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin.

Authors:  W A Creasey; L S McIntosh; T Brescia; O Odujinrin; G T Aspnes; E Murray; J C Marsh
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

2.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

3.  Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia.

Authors:  B C Baguley; E M Falkenhaug
Journal:  Cancer Chemother Rep       Date:  1971-06

Review 4.  Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

Authors:  F M Schabel; D P Griswold; T H Corbett; W R Laster
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

5.  The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.

Authors:  A L Harris; D G Grahame-Smith
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia.

Authors:  D E Brenner; P H Wiernik; M Wesley; N R Bachur
Journal:  Cancer       Date:  1984-03-01       Impact factor: 6.860

7.  Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.

Authors:  J J Lokich
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

8.  Clinical pharmacology of bruceantin by radioimmunoassay.

Authors:  K L Fong; D H Ho; R S Benjamin; N S Brown; A Bedikian; B S Yap; C L Wiseman; W Kramer; G P Bodey
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.

Authors:  W Kreis; C Hession; A Soricelli; K Scully
Journal:  Cancer Treat Rep       Date:  1977-10

10.  Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation.

Authors:  T M Woodcock; D S Martin; L A Damin; N E Kemeny; C W Young
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

View more
  23 in total

1.  An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics.

Authors:  C Meille; A Iliadis; D Barbolosi; N Frances; G Freyer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-12-24       Impact factor: 2.745

2.  Relationship between the pharmacokinetics and toxicity of mitozolomide.

Authors:  D J Kerr; J A Slack; P Secrett; M F Stevens; G R Blackledge; C Bradley; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Aspects of cytotoxic drug penetration, with particular reference to anthracyclines.

Authors:  D J Kerr; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Pharmacokinetics in experimental and clinical chemotherapy.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.

Authors:  C Fournier; P Vennin; B Hecquet
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  A limited sampling method for estimation of the carboplatin area under the curve.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Authors:  G Powis; P Reece; D L Ahmann; J N Ingle
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 8.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

9.  Variability in the pharmacokinetics of epirubicin: a population analysis.

Authors:  J R Wade; A W Kelman; D J Kerr; J Robert; B Whiting
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Pharmacokinetics of thio-TEPA at two different doses.

Authors:  B Hagen; R A Walstad; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.